RPG Life Sciences Ltd

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed about an Analyst/Institutional Investors Meet to be held on September 2, 2026, in Mumbai. The meeting will be participated by the company and will be held in a physical format. The details of the meeting are as follows: Date: September 2, 2026, Time: 10:00 A.M. IST, Venue: Mumbai, Mode: Physical, Nature of Meeting: Group Meet.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed about the Schedule of Analyst/Institutional Investors Meet, to be participated by the Company on August 25, 2026, at 10:00 A.M. in Mumbai.

RPG Life Sciences Ltd

RPG Life Sciences Ltd announced the resignation of Mr. Deepak Shukla, Chief Executive - API Business, effective August 14, 2026, due to his appointment as Chief Executive Officer of RPG Active Pharma Limited, a wholly-owned subsidiary.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has completed the transfer of its Active Pharmaceuticals Ingredients (API) business to RPG Active Pharma Limited, a wholly-owned subsidiary, effective August 15, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed the exchange about further investment in its wholly-owned subsidiary, RPG Active Pharma Limited, by subscribing to its rights issue of equity shares.

RPG Life Sciences Ltd

RPG Life Sciences Ltd announced an analyst/institutional investors meet on August 13, 2026, at 9:00 AM IST, to be held at Emkay Confluence in Mumbai. The meet is subject to change due to exigencies.

RPG Life Sciences Ltd

RPG Life Sciences Ltd announced the superannuation of Mr. Samir Rane, Vice President, Sales & Marketing - Main Division, effective July 31, 2026, due to his retirement upon attaining the age of superannuation.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced a special window for lodgement of transfer and dematerialization requests for physical securities sold/purchased prior to April 1, 2019. The company has published newspaper advertisements in Business Standard and Mumbai Lakshadeep on July 31, 2026, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026. The information will also be hosted on the company's website.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced a strategic API initiative to accelerate its next phase of growth. The company will transfer its API business to a wholly owned subsidiary, RPG Active Pharma, and raise an initial amount of up to INR 243 crore from funds managed by InvAscent. RPG Active Pharma will also acquire 100% equity share capital of Actis Generics Private Limited.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the execution of a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited, for Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026, subject to customary conditions.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has executed a Business Transfer Agreement for the sale of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Limited, for a consideration of Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the outcome of its board meeting, where it approved the execution of a business transfer agreement for the sale of its API business to its wholly-owned subsidiary, RPG Active Pharma Limited, for a consideration of Rs. 33.55 crore. The sale is expected to be completed by September 30, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website. The company has also announced a special window for re-lodging transfer requests of physical shares, as per SEBI's circular.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has released an investor presentation for its unaudited financial results for the quarter ended June 30, 2026. The presentation highlights the company's Q1 FY27 performance, including historical profit and loss numbers for certain sales divisions. The company operates in the pharmaceutical segment and has a strong global presence.

RPG Life Sciences Ltd

RPG Life Sciences Ltd reported Q1 FY27 financial results with revenue growth of 15.8% and EBITDA growth of 17.9%, with EBITDA margin expanding to 24.5%. The company's Domestic Formulations business outperformed the Indian pharma market growth rate, growing at 14.8%. The company also entered the Top 50 Indian Pharma Companies list in June 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The company's revenue from operations was Rs. 19,569 lakhs, with total income of Rs. 19,985 lakhs. Expenses include cost of materials consumed, purchases of stock-in-trade, changes in inventories, employee benefits expense, and finance cost.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 19,569 lakhs and total income at Rs. 19,985 lakhs. The company's board of directors has approved the results, and the independent auditor's review report is also attached.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the completion of the second consecutive five-year term of Ms. Zahabiya Khorakiwala as an Independent Director, effective July 26, 2026. The Sustainability and Corporate Social Responsibility Committee has been reconstituted with new members.

RPG Life Sciences Ltd

RPG Life Sciences Ltd held its Nineteenth Annual General Meeting (AGM) on July 23, 2026, where all resolutions were passed with requisite majority. The meeting was conducted through video conferencing, and the voting results were disclosed. The company provided the facility of remote e-voting and e-voting at the AGM.

RPG Life Sciences Ltd

RPG Life Sciences Ltd held its 19th AGM on July 23, 2026, where all resolutions were passed with a majority. The company declared a 300% dividend of ₹24 per equity share. The meeting was conducted through video conferencing and e-voting was facilitated for members who did not attend in person.